Jim Cramer says investors should buy these 11 recently-boosted dividend stocks

Jim Cramer says investors should buy these 11 recently-boosted dividend stocks


CNBC’s Jim Cramer on Thursday offered investors a list of dividend stocks with yields that recently increased, that he believes buyers should add to their portfolio.

Dividends are a generally “unassailable defense against a volatile market,” the “Mad Money” host said, which means that they can be attractive additions to the portfolio of an investor worried about Russia’s invasion of Ukraine, soaring inflation and Covid fears that have roiled the market in recent weeks.

“You want bountiful dividends that are also safe, and the best way to determine a dividend’s safety is by searching for the companies that have recently raised their payouts, because that’s the ultimate sign of confidence in the future,” Cramer said. “Plus, with interest rates on the rise, only the dividend boosters can keep up with the bond market competition,” he added.

To come up with his list, which he said are the “biggest dividend raisers of 2022 so far,” Cramer only included stocks which raised dividends this year by more than 20%. Using this criteria, he shrunk the list of hundreds of stocks listed in the S&P 500 to 27 names, then down to 11 stocks that he believes can outpace inflation and be attractive additions to buyer’s portfolios.

Here is the list:

  1. Pioneer Natural Resources
  2. Coterra Energy
  3. Devon Energy
  4. Halliburton
  5. Tractor Supply
  6. Best Buy
  7. Dollar General
  8. NXP Semiconductors
  9. Prologis
  10. Wells Fargo
  11. American Express

“When the Fed is tightening to combat rampant inflation, I don’t want you to overthink it — you want to circle the wagons around companies that are rapidly raising their dividends,” Cramer said.

Disclosure: Cramer’s Charitable Trust owns shares of Devon, Halliburton and Wells Fargo.

Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.

Disclaimer

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money TwitterJim Cramer TwitterFacebookInstagram

Questions, comments, suggestions for the “Mad Money” website? [email protected]





Source

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Business

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg | Getty Images Johnson & Johnson on Wednesday said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots. The FDA approved the pill, Icotyde, to treat […]

Read More
Macy’s store revamp shows progress, but company expects sales to fall this year
Business

Macy’s store revamp shows progress, but company expects sales to fall this year

Macy’s on Wednesday beat Wall Street’s quarterly sales and profit expectations as its namesake brand showed signs of progress, yet still gave a cautious outlook for the year ahead. For the fiscal year, the company – which includes its namesake chain, higher-end department store Bloomingdale’s and beauty retailer Bluemercury – said it expects sales of […]

Read More
Disney embarks on new chapter as Josh D’Amaro takes over as CEO
Business

Disney embarks on new chapter as Josh D’Amaro takes over as CEO

Larissa Manoela and Josh D’Amaro, Chairperson of Walt Disney Parks and Resorts, wave to the audience after Panel Disney Experiences during Day 2 of the D23 Brazil: A Disney Experience at Transamerica Expo Center on November 09, 2024 in Sao Paulo, Brazil. Ricardo Moreira | Getty Images Disney is turning the page on a new […]

Read More